The market value fell by $600 million Chronic Cough BLU-5937 concept verification fell as expected.

ON JULY 06, 2020, BELLUS HEALTH ANNOUNCED RELIEF DATA FROM A CLINICAL TRIAL OF THE CONCEPTUAL VERIFICATION OF P2X3 RECEPTOR BLOCKERS, AND THE SAFETY ADVANTAGES OF BLU-5937 HAVE BEEN SEEN, BUT THE CLINICAL BENEFITS ARE NOT AS EXPECTED, AND IN PATIENTS WITH RELAPSED CHRONIC COUGH, BLU-5937 VSPlacebo, cough frequency decreased by 17%, did not reach the clinical end, unexpected failure, as a result, the company's market value plummeted by $600 million, down -71%!Several points of view have been described in previous articles: 1Chronic cough has a huge unmet clinical need, P2X3 has been a sure target for chronic cough; Gefapixant was the first to complete two phase 3 critical clinical trials, and cough-1/2 top-line data showed that gefapixant 45mg reached the clinical primary endpoint; First-in-class drug gefapixant due to poor selectivity, taste disorder is a common concern; The article mentions BLU-5937, whose first proof-of-concept clinical trial ISFT is highly anticipated because of its high lysy selectivity and potential safety advantages for P2X3, and the first proof-of-concept clinical trial of THE drug, THE
BLU-5937
(NCT03979638) clinical trial design
INTHET population, BLU-5937 failed to significantly reduce the number of coughssevere cough patients-5937 can significantly reduce the cough frequency of patients
such unexpected failure, BELLUS Health always have to find a way to continue, for now, BELLUS Health gives two hope:first hope: first, to find a significant clinical benefit of the subgroup of people, data show that BLU-5937 can significantly reduce the frequency of coughing patients with severe cough, BLU-5937 vsplacebo, cough frequency decreased by 32%, so-called severe cough is hourly (median) cough number 32BLU-5937 can significantly reduce the frequency of coughing in patients with severe coughs
The clinical benefits of BLU-5937 increase with the severity of coughing
second hope: the proportion of attention-driven taste abnormalities is indeed low, BLU-5937 is about 5-10%THE taste abnormality caused by BLU-5937 is the least commonBELLUS Health pipeline, BLU-5937 is a concern, the company certainly can not easily give upTo sum up, 1 Blu-5937 is also very low in patients with taste abnormalities due to its extremely high P2X3 receptor selectivity; Blu-5937 has the highest share of hP2X3 receptors compared to gefapixant and S-600918, but BELLUS Health noted on a conference call that the higher the drug's affinity to P2X3 receptors, the worse the clinical benefits of the drug may be; This subgroup analysis showed significant clinical benefits of the drug in patients with severe cough BLU-5937 is relatively of similar drugs Based on this, the BLU-5937 will have an important action next: 1 In the fourth quarter of 2020, BLU-5937 will conduct a 2b clinical trial in patients with severe cough to regain confidence; In addition to chronic cough indications, a new indication is developed, namely itching The company expects the two clinical trials to cost $20 million and $10 million, respectively to date, 1 Mercadon gefapixant remains the leading drug of its kind, and it is expected to disclose more detailed clinical trial data, in particular drug safety data, and 2 We look forward to the launch of a new clinical trial by BLU-5937 to further confirm the clinical benefits of the drug in patients with severe cough This article no longer covers diseases, targets and potential market introductions, please refer to the author of the previous.